Quotient Clinical, a provider of outsourced, early-stage drug development services to the pharmaceutical industry, has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital
for an undisclosed sum. Quotient Clinical has developed a platform that offers an integrated approach to formulation development, real-time drug product manufacturing, and clinical testing.
Quotient Clinical is currently part of Quotient Group, which is disposing of the business and represents a primary management buyout. The transaction is subject to standard regulatory clearances.
Source: Bridgepoint Development Capital